17:44 , Nov 15, 2016 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds Aripiprazole-based biased agonists at the dopamine D2 receptor that activate GNAI1 but not arrestin beta 2 (ARRB2) could be useful as probes for D2 receptor-induced GNAI1 signaling in psychiatric and neurodegenerative diseases. Chemical...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: µ opioid receptor (MOR; OPRM1); G protein α inhibiting activity polypeptide 1 (GNAI1)

Neurology INDICATION: Pain In vitro and mouse studies identified a biased agonist of MOR signaling that could help treat pain. In silico screening of a library of 3 million small molecules, each in 1.3 million differing conformations,...
07:00 , Sep 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Biased against pain

In a departure from the rote tweaking of morphinan structures to find better and safer opioids, an academic collaboration has used a powerful, computer-based screen of more than 3 million molecules to identify a new...